NRAS Gene Mutation clinical trials at UCLA
2 in progress, 1 open to eligible people
KIN-2787 in Participants with BRAF And/or NRAS Mutation Positive Solid Tumors
open to eligible people ages 18 years and up
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or metastatic solid tumors.
Los Angeles, California and other locations
Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
Sorry, in progress, not accepting new patients
The purpose of this study is to assess 2 different doses of onvansertib to select the lowest dose that is maximally effective, and to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of onvansertib in combination with FOLFIRI + bevacizumab or FOLFOX + bevacizumab in patients with KRAS or NRAS-mutated metastatic colorectal cancer (CRC) in the first-line setting.
Los Angeles, California and other locations
Our lead scientists for NRAS Gene Mutation research studies include J. Randolph Hecht, MD Bartosz Chmielowski, MD, PhD.
Last updated: